Congruence Therapeutics

Congruence is a computationally-driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function. Our proprietary scalable platform, Revenir™, captures the biophysical features of proteins across their conformational ensembles, in order to identify novel allosteric and cryptic pockets which are virtually screened to generate novel chemical matter.

entos pharmaceuticals

Entos Pharmaceuticals Inc. is a clinical-stage genetic medicines company. A new reality in genetic medicine lies ahead, one that will be ushered in with the advent of safe, effective, and redosable nucleic acid delivery technologies. At Entos, we develop next generation genetic medicines using our proprietary Fusogenix proteolipid vehicle (PLV) drug delivery system. Fusogenix PLVs are formulated with FAST proteins to enable the delivery of nucleic acid into target cells through direct fusion.

ISCT, International Society for Cell & Gene Therapy

ISCT is a global association driving the translation of scientific research to deliver innovative cellular therapies to patients.

Biomedical Engineering Society - Toronto Metropolitan University Chapter (BMES TMU)

We are Toronto Metropolitan University's student branch of the Biomedical Engineering Society (BMES TMU). BMES TMU's workshops and events aim to improve the professional competence of all interested students in the biotechnology sector.

cpgr

The Centre for Proteomic and Genomic Research (CPGR) plays a pivotal role in advancing South Africa’s ambition to emerge as a leading bio-economy in the 21st century. As a pioneering force in OMICS technology encompassing Genomics, Proteomics, and Bioinformatics, CPGR delivers comprehensive solutions to clients, fostering the growth of the biotechnology sector. Integrating cutting-edge OMICS technologies with bio-computational pipelines, CPGR supports projects in the life sciences and biomedical field in South Africa, all managed through an ISO 9001:2015 certified and compliant quality management system. Founded in 2006 through an initiative by the South African Department of Science and Technology (DST; now the Department of Science and Innovation/DSI), CPGR received financial support from the Technology Innovation Agency (TIA) to boost bio-economic development. This involved making capital-intensive and costly-to-maintain capacity accessible to scientists in academia and industry, thereby enhancing their capacity for publishing and patenting. CPGR's OMICS accelerator programs have led to the establishment of Artisan Biomed (established in 2015, now known as Mediclinic Precise) and, more recently, D-CYPHR (2022). Additionally, CPGR hosts DIPLOMICS, a substantial infrastructure program initiated by the DST. Since its inception, CPGR has facilitated over 1 200 OMICS research projects, consistently striving to implement the latest OMICS solutions to enrich the biotechnology sector in South Africa. For more information about CPGR: www.cpgr.org.za Connect with us: linktr.ee/thecpgr